NEW YORK (GenomeWeb) – Veracyte announced today that it has priced a public offering of 5 million shares of its common stock at $6 per share, for gross proceeds of $30 million.
The offering’s underwriters have also been granted a 30-day option to buy an additional 750,000 shares at the public offering price, minus underwriting discounts and commissions.